A medical part can pass biocompatibility, meet every tolerance, and clear every inspection along the way, then fail validation because nobody confirmed a sterilization method until the mold was already steel. Wanox has seen this on EtO projects, where venting features had to be added to a finished tool so the gas could reach every cavity, and validation had to start again.
Modifying the mold is the visible cost. Your launch plan absorbs the rest, because every week spent reworking steel and rerunning validation keeps the product out of market. That exposure usually traces back to an open sterilization requirement, or one written too loosely to design against, before anyone cut the tool.
The Sterilization Decision That Reopens a Finished Mold

Two decisions repeatedly cause delays. The first is releasing design and tooling before anyone confirms the sterilization method. The second is assuming the chosen method will accept whatever part arrives.
Each method asks something different of the design.
- EtO needs venting geometry so the gas can penetrate every cavity.
- Gamma and electron-beam (e-beam) radiation need dose mapping across the way parts are packed for sterilization, so no area of the part receives too little or too much exposure.
Before design freeze, a sterilization change means revising a drawing. After tooling, it means modifying the mold and repeating validation. Wanox’s position is that confirming the method before design freeze cuts both cost and delay.
Why “Compatible With Sterilization” Fails at Validation

If your drawing says “compatible with sterilization,” it gives your manufacturer nothing to design against. Compatibility depends on four things.
- The radiation dose range (measured in kGy) or the EtO gas concentration
- The exposure time
- How densely parts are packed in each sterilization load
- For reusable devices, how many re-sterilization cycles the part must survive
Two parts with identical geometry can behave differently when run at different dose or cycle settings. A supplier quoting against your vague requirement is quoting on an assumption, and validation is where you test that assumption on your timeline.
Before production starts, Wanox requires you to supply the intended method, the dose range or EtO parameters, the cycle count, and the load configuration.
Responsibility for testing is settled at that stage. Depending on the project, Wanox either coordinates with the sterilization provider or directly supports dose mapping and validation testing. The parties agree on the split case by case, so neither assumes the other has run the tests.
Single-Method Designs Leave Your Export Timeline Exposed

If you can sterilize your part only one way, your launch date depends on a regulatory decision in Washington and on Canadian reactor schedules. You can influence neither from a factory in Asia. Most Wanox buyers manufacture in the region and ship into US or EU regulated markets, so a disruption that starts on another continent still lands on their shipping plan.
For EtO, the risk is regulatory. In March 2026, the US Environmental Protection Agency proposed repealing the emissions limits it had tightened on sterilization plants in 2024. Lawmakers and environmental groups have opposed the move. As of October 2026, the final rule is still pending; any outcome may be challenged in court, and state regulators can keep their own limits. EtO handles roughly half of all sterilized medical devices in the US, so sterilizer capacity there hangs on a decision nobody can yet predict.
For gamma, the risk sits with supply. Cobalt-60, the radioactive source behind gamma sterilization, treats about 40% of single-use medical devices in the US, and the country imports all of it.
Supply tightened between 2018 and 2024, bringing processing restrictions and extended lead times for some device makers. Two major Canadian reactor refurbishment programs finish in 2026 and 2033, and the first US domestic production is targeted for the mid-2030s.
Neither risk sits inside your control. Neither risk sits within your control. Where feasible, Wanox recommends designing for compatibility with a second sterilization method from the start, because establishing dual compatibility early avoids requalifying the part if one route tightens.
Two Gaps That Stall Most Sterilization Specifications

Both gaps share a pattern. You name the method and stop there, leaving out the details that decide whether the part passes validation. Wanox treats a sterilization specification as complete when it covers five items.
- The method
- Dose or exposure parameters
- Resterilization cycle count
- Load configuration
- Target market, which tells your manufacturer whose regulatory requirements the part must meet at import
Load configuration and cycle count are the two most often missing. Load configuration describes how parts sit in the sterilization load, and without it, a dose map cannot reflect what happens in your production runs. Cycle count matters for any reusable device, because a part validated for a single cycle carries no evidence it will survive repeated re-sterilization over its service life.
What This Prevents
Sterilization is easy to treat as the sterilization provider’s problem. Yet the method shapes the mold, the specification shapes validation, and a single-method design ties your launch to an EPA ruling and a reactor schedule. Wanox’s approach brings all three decisions forward to design freeze, the last point where a sterilization change still means revising a drawing.
Contact Wanox to confirm your sterilization method before design freeze.



